Reuters -- Cephalon Inc said on Monday that an experimental drug for a rare type of inflammation of the esophagus showed mixed results in a mid-to-late stage clinical trial, sending its shares down more than 9 percent.
Reuters -- Cephalon Inc said on Monday that an experimental drug for a rare type of inflammation of the esophagus showed mixed results in a mid-to-late stage clinical trial, sending its shares down more than 9 percent.
